Scott Thacher, CEO and founder of Orphagen Pharmaceuticals, shared a post on LinkedIn:
“Texas calls.
The Cancer Prevention and Research Institute of Texas (CPRIT) announced today that it plans to award Orphagen a $10.2 M product development grant over three years to partially fund the final steps towards IND filing and a Phase 1 clinical trial of OR-449, a novel therapeutic candidate for an intractable cancer, adrenocortical cancer (ACC). OR-449 may be developed subsequently in head and neck and lung squamous cancers as a therapy for the 3-10% of these tumors where its target is highly expressed.”
Read more about Orphagen.
For more updates, follow OncoDaily.